Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E; OASIS-2 Investigators. O'Riordan W, et al. Among authors: loh e. Lancet Infect Dis. 2019 Oct;19(10):1080-1090. doi: 10.1016/S1473-3099(19)30275-0. Epub 2019 Aug 29. Lancet Infect Dis. 2019. PMID: 31474458 Clinical Trial.
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. O'Riordan W, et al. Among authors: loh e. N Engl J Med. 2019 Feb 7;380(6):528-538. doi: 10.1056/NEJMoa1800170. N Engl J Med. 2019. PMID: 30726689 Clinical Trial.
Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Stets R, et al. Among authors: loh e. N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201. N Engl J Med. 2019. PMID: 30726692 Clinical Trial.
Omadacycline for Bacterial Infections. Reply.
Garrity-Ryan L, Loh E. Garrity-Ryan L, et al. Among authors: loh e. N Engl J Med. 2019 May 23;380(21):2073-2074. doi: 10.1056/NEJMc1903821. N Engl J Med. 2019. PMID: 31116928 No abstract available.
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. Ellis-Grosse EJ, et al. Among authors: loh e. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53. doi: 10.1086/431675. Clin Infect Dis. 2005. PMID: 16080072 Clinical Trial.
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G. Sacchidanand S, et al. Among authors: loh e. Int J Infect Dis. 2005 Sep;9(5):251-61. doi: 10.1016/j.ijid.2005.05.003. Int J Infect Dis. 2005. PMID: 16099700 Free article. Clinical Trial.
A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group. Oliva ME, et al. Among authors: loh e. BMC Infect Dis. 2005 Oct 19;5:88. doi: 10.1186/1471-2334-5-88. BMC Infect Dis. 2005. PMID: 16236177 Free PMC article. Clinical Trial.
486 results